T-Cell Prolymphocytic Leukemia

This is a type of prolymphocytic leukemia that starts in T-cells. T-cells are another type of white blood cell that helps fight infection. This leukemia involves a large number of these T-cells in the blood and can grow quickly, often leading to a shorter lifespan.

Condition

What people with T-Cell Prolymphocytic Leukemia report

Every report comes from a Lived member, sent anonymously.

Have you tried Lemtrada (Alemtuzumab) for T-Cell Prolymphocytic Leukemia?

NameHow it went

About T-Cell Prolymphocytic Leukemia

What It Is

T-cell prolymphocytic leukemia (T-PLL) is a rare blood cancer of T cells, a type of white blood cell (lymphocyte) that helps direct the immune system. In T-PLL, one abnormal T cell multiplies out of control, and its copies build up in the blood, bone marrow, spleen and other tissues. It mainly affects older adults and is usually aggressive, meaning it tends to grow quickly once it becomes active. Most people come to medical attention with a very high white blood cell count, an enlarged spleen that can cause fullness or discomfort in the upper left abdomen, swollen lymph nodes, and symptoms such as fevers, night sweats or weight loss. About a quarter develop a skin rash or skin lumps, and some have fluid around the lungs or swelling in the legs. As the leukemia crowds the bone marrow, red cells and platelets fall, which can cause tiredness and easy bruising. T-PLL was once called T-cell chronic lymphocytic leukemia, but it is a different disease from the much more common chronic lymphocytic leukemia (CLL), which arises from B cells and usually behaves far more slowly.

Causes & Risk Factors

The cause of T-PLL is not known. The leukemia cells almost always carry acquired changes in their chromosomes, most often a rearrangement that switches on a gene called TCL1, which drives the cells to grow and survive. These changes develop in the cancer cells during a person's life; they are not usually inherited and are not passed on to children. The disease is more common with older age (most people are over 60 at diagnosis), in men, and in people who have had another cancer. Rare cases have occurred in young people with ataxia-telangiectasia, an inherited disorder that affects DNA repair. No lifestyle factor is known to cause T-PLL.

How It's Diagnosed

T-PLL is usually diagnosed from a blood sample. A complete blood count often shows a very high lymphocyte count, and a specialist examines the cells under the microscope. Flow cytometry, a test that reads the protein markers on the surface of each cell, confirms that the cells are mature T cells and that they all come from a single abnormal cell. Chromosome and FISH (fluorescence in situ hybridization) testing look for the genetic changes typical of T-PLL, especially those involving TCL1. Because several other T-cell leukemias and lymphomas look similar, these genetic results are now central to confirming the diagnosis. A blood test for HTLV-1, a virus that causes a look-alike called adult T-cell leukemia/lymphoma, helps rule that disease out. A bone marrow biopsy is not always needed to make the diagnosis, but it is often done to establish a baseline and later to confirm whether treatment has cleared the disease. Scans show how large the spleen, liver and lymph nodes are.

Treatment Options

Treatment depends on whether the disease is active. About a third of people are diagnosed while they have no symptoms and a stable blood count. Starting treatment at that point has not been shown to help, so the usual approach is careful monitoring with regular blood counts and examinations. This early phase eventually progresses in everyone, and treatment begins when symptoms appear, organs enlarge, blood counts fall or the lymphocyte count rises quickly. For active disease, the most effective first treatment is alemtuzumab (Campath), an antibody that attaches to a marker called CD52 on lymphocytes and destroys them. It is given into a vein, usually three times a week for up to about 12 weeks, and most people who receive it as their first treatment respond. In the US it is approved for a different leukemia and used for T-PLL on the basis of specialist consensus. Standard chemotherapy combinations work poorly in T-PLL and are not a first choice. Alemtuzumab weakens the immune system for months after the last dose. People take preventive antibiotics and antiviral medicine during treatment and for months afterward, and are checked regularly for reactivation of cytomegalovirus (CMV), a common virus that can cause serious illness in people with weakened immunity. Remissions after alemtuzumab alone are usually temporary. For people who respond and are fit enough, an allogeneic stem cell transplant (using blood-forming cells from a donor) is the only treatment with a chance of long-term control or cure. It is intensive and carries serious risks, and only about a third to a half of people with T-PLL are able to have one; roughly a third of those who do are alive and well long term. When the leukemia returns, options are limited, and clinical trials of newer targeted medicines that block growth signals inside the leukemia cells are an important choice to ask about.

What to Expect

T-PLL is a serious diagnosis, and outcomes are hard. In a recent national study, half of people lived longer than about 13 months after diagnosis, and around 1 in 10 were alive at five years. These figures include many older people who could not have intensive treatment, and individual outcomes vary, especially for those who reach a transplant in remission. Treatment is usually led by a hematologist at a center experienced in rare leukemias. The alemtuzumab phase means frequent infusion visits, close blood monitoring and attention to infection risk, and many people feel tired during this time. A transplant involves weeks in or near the hospital, a long recovery and ongoing follow-up for complications. Because the disease can return, regular blood counts continue after treatment ends. For people in the early symptom-free phase, life may be largely unchanged for a time, but regular follow-up appointments matter because progression can be quick. Given the realities of this disease, it is worth discussing goals of care and support options, including palliative care, early alongside treatment.

When to Seek Help

See a doctor if blood tests show an unexplained high lymphocyte count, or if you notice persistent fullness in the upper left abdomen, swollen lymph nodes, drenching night sweats, unexplained weight loss or a new widespread rash. If you are being monitored without treatment, contact your hematology team if new symptoms appear, such as a growing spleen or lymph nodes, new skin changes, unusual tiredness or easy bruising, rather than waiting for the next scheduled visit. During and for months after alemtuzumab, call your treatment team right away for a fever or any other sign of infection, since infections can become serious quickly when the immune system is suppressed.

Questions to Ask Your Doctor

  1. 1.Is my disease active now, or is monitoring a reasonable choice, and what changes would mean it is time to start treatment?
  2. 2.Should my care be coordinated with a center that has experience treating T-PLL?
  3. 3.Am I a candidate for a donor stem cell transplant, and what would we need to arrange to make that possible if I respond to treatment?
  4. 4.What infections should I watch for during and after treatment, and how long will I need preventive medicines?
  5. 5.Are there clinical trials I should consider now or if the leukemia comes back?

Last reviewed • Oct 2026

Educational content, not medical advice.